Conjugate company Avidity preps for first dystrophy study with $100M series C

With fresh cash, new CEO, Avidity will build a musculoskeletal pipeline while looking beyond to other areas

Avidity’s $100 million series C round will allow it to evaluate clinical proof of concept for the first antibody-oligonucleotide conjugate from its platform. The company believes it can also fund early clinical development of a second program while allowing Avidity to explore further uses of its technology in areas beyond muscle disorders.

Avidity Biosciences Inc. has selected a

Read the full 570 word article

How to gain access

Continue reading with a
two-week free trial.